leisure time -WSS

leisure time

author：entertainment 2025-08-27 16:48:03 - browse：79

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Why we need mandatory labeling of GMO products

hotspot

WSS

Medicare drug price negotiation’s day in court

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Some medical students still think black patients feel less pain

Decentralized clinical trials need collaboration to achieve wider use

Louisiana bill approved classifying abortion pills as controlled substances

focus

leisure time

Sign up for D.C. Diagnosis

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

Woodcock on FDA’s accelerated approval and her next chapter

Guidelines to prevent youth baseball injuries need more muscle

Quicker fix for pulse oximeters urged during FDA public meeting

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Malaria cases in Florida and Texas: Here’s what you need to know

Even great ERs can’t make up for American health disparities

Heart attack and stroke risk calculators need revising

Quicker fix for pulse oximeters urged during FDA public meeting

entertainment

Pharma’s losing bet in New Jersey

Woodcock on FDA’s accelerated approval and her next chapter

Unmasking the 'centricity' illusion in clinical trials

Why we need mandatory labeling of GMO products

Achieving telehealth equity for people with hearing loss

Asahi Kasei to buy Calliditas, picking up kidney disease drug

focus

hotspot

hotspot

hotspot